Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial
{{output}}
Acquired pure red cell aplasia (aPRCA) is rare and challenging to treat. We investigated the efficacy and safety of sirolimus plus roxadustat in patients with aPRCA (Chinese Clinical Trial Register number, ChiCTR2200065107). We enrolled 82 patients with aPRCA ... ...
